If you've been researching ibogaine long enough, you've found the deaths. They're not hidden. Researchers have compiled case reports. Journalists have written about them. Families have shared their stories.
- Roughly 40 ibogaine-related deaths are documented in the medical literature — against an estimated 50,000–100,000 total administrations globally.
- Nearly every case involved missed cardiac screening, undisclosed drug interactions, inadequate monitoring, or an unsupervised setting. Very few look like ibogaine killing a healthy, screened, monitored patient.
- A 12-lead ECG with QTc measurement before treatment is non-negotiable. Ibogaine is contraindicated above certain QTc thresholds — this is not a box to check, it is the safety protocol.
- Ibogaine's legal status in the US has pushed people toward riskier underground settings. That is also part of the deaths story.
What's harder to find is a clear account of what actually happened in those cases, and what, if anything, could have prevented them.
This is that piece.
How many deaths are we talking about
The most comprehensive review of ibogaine-related deaths in the medical literature documented 33 cases through 2016. Other analyses, extending through the early 2020s, put the total closer to 40. Given that ibogaine has been administered to tens of thousands of patients globally (estimates range widely, but 50,000 to 100,000 total administrations is plausible), that's a small absolute number.
That doesn't mean it's acceptable. It means it's worth understanding.
What the cases actually show
Researchers who have analyzed these deaths consistently identify a small set of contributing factors. They appear in case after case.
Cardiac abnormalities that weren't caught. A significant proportion of documented deaths involved patients with pre-existing QT prolongation, structural cardiac abnormalities, or a family history of sudden cardiac death that was never identified because no one looked. No ECG. No cardiovascular screening. No baseline established.
Drug interactions. Several deaths involved patients who had not cleared medications that interact dangerously with ibogaine. The opioid picture is more nuanced than it first appears: some clinics actually administer short-acting opioids (typically oral morphine) as a stabilization tool, giving a final dose as few as 4 to 12 hours before ibogaine. The documented risk is not opioids categorically but specific compounds — fentanyl, whose fat-soluble metabolites accumulate unpredictably and may not clear on a standard timeline; methadone, which has its own QT-prolonging properties that interact directly with ibogaine's cardiac profile; and 7-hydroxymitragynine, the potent opioid alkaloid in kratom, which requires a clinic-supervised washout period of several days before treatment can safely proceed. Stimulants in the system. In some cases, patients who were not honest with providers about what they had taken. In a few cases, providers who didn't ask.
Inadequate monitoring during treatment. Ibogaine's cardiac effects peak several hours into the treatment, not immediately at dosing. Cases where monitoring ended after the initial hours, or where no continuous cardiac monitoring was in place at all, represent a meaningful share of preventable deaths.
Excessive or inappropriate dosing. A smaller number of cases involve dose errors, or situations where patients received flood doses without adequate pre-treatment assessment of their weight, health status, and metabolic clearance.
Poor setting without medical response capability. Deaths that might have been survivable with immediate medical response were not survivable in settings without IV access, emergency medications, or the ability to call for help.
The pattern
When you read through these cases, a pattern emerges that is genuinely important: almost none of them look like ibogaine simply killing a healthy, screened, properly monitored patient.
That doesn't mean they aren't tragic. It doesn't mean the people who died were careless or reckless. In many cases, they were desperate, trying to get off opioids in an underground setting because no legal, supervised option existed where they lived. The legal status of ibogaine in the United States has pushed people toward riskier situations. That is also part of this story.
But it does mean that the risk the deaths represent is, largely, the risk of unscreened treatment in unsupervised settings. Not the risk of ibogaine itself when administered with appropriate care.
What "appropriate care" actually looks like
The minimum standard at any clinic worth considering:
A 12-lead ECG with QTc measurement before treatment. Ibogaine is contraindicated above certain QTc thresholds. This isn't optional.
Continuous cardiac monitoring (telemetry) throughout the treatment, not just at the start. Arrhythmias can occur hours in.
A complete and honest medication history, with verified clearance of contraindicated substances before dosing.
On-site medical staff with emergency response capability: IV access, reversal agents, ability to manage cardiac events.
A thorough intake that goes beyond a form. A conversation. An opportunity to catch what paperwork misses.
These aren't luxury features. They are the difference between a manageable risk profile and the risk profile documented in the death cases.
How to use this information
The deaths in the record are real. They deserve to be taken seriously, not explained away.
What they don't justify is the conclusion that ibogaine is categorically too dangerous to consider. They justify a clear-eyed assessment of the setting you'd be in, the screening you'd receive, and the monitoring in place during your treatment.
Ask the clinics you're considering about their cardiac screening protocol. Ask about their monitoring. Ask what happens if something goes wrong at 3am on night two. The answers will tell you a lot.